SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice

FASEB Journal

Volumn 16, Issue 7, 2002, Pages 681-690

  Douglas Laird, A ^a   Christensen, James G ^a   Li, Guangmin ^a   Carver, Jeremy ^a   Smith, Kimberly ^a   Xin, Xiaohua ^a   Moss, Katherine G ^a   Louie, Sharianne G ^a   Mendel, Dirk B ^a   Cherrington, Julie M ^a  

^a SUGEN INC   (United States)

Author keywords

Angiogenesis; Kinase inhibitor; Platelet derived growth factor; VEGF

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD VESSELS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; KINETICS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 0036242810     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
2. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1
3. Matrix metalloproteinases: Biologic activity and clinical implications
4. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
5. VEGF: An update on biological and therapeutic aspects
6. Signal transduction by fibroblast growth factor receptors
7. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes
8. Protein kinase inhibitors: Structural determinants for target specificity
9. SU6668, a broad spectrum angiogenesis inhibitor, exhibits potent antitumor activity in xenograft models, including regression of established tumors
10. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
11. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
12. Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea pigs
13. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF
14. Tumor induction of VEGF promoter activity in stromal cells
15. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
16. Is angiogenesis inhibition the Holy Grail of cancer therapy?
17. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
18. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
19. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor
20. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor (VEGF) receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
21. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
22. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal